-
Product Insights
Addictive Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Addictive Disorders - Drugs In Development, 2023’, provides an overview of the Addictive Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Addictive Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Smoking Cessation – Drugs In Development, 2023
Global Markets Direct’s, ‘Smoking Cessation - Drugs In Development, 2023’, provides an overview of the Smoking Cessation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EORA-101 in Opium (Opioid) Addiction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.EORA-101 in Opium (Opioid) Addiction Drug Details:EORA -101 is under development for the treatment of smoking...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Stemirac in Traumatic Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Stemirac in Traumatic Spinal Cord Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Stemirac in Traumatic Spinal Cord Injury Drug Details: Stemirac...
-
Product Insights
Daniel Corp – Lake Eola Apartments – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our Daniel Corp - Lake Eola Apartments - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
DIX Dev – VIVE on EOLA Residential Tower – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our DIX Dev - VIVE on EOLA Residential Tower - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EORA-101
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EORA-101 Drug Details EORA -101 is under development for the treatment of smoking cessation...
-
Product Insights
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Orexin Receptor Type 1 – Drugs In Development, 2022, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Orexin Receptor Type 1 (Hypocretin...